The Phytochemical Indicaxanthin Synergistically Enhances Cisplatin-Induced Apoptosis in HeLa Cells via Oxidative Stress-Dependent p53/p21<sup>waf1</sup> Axis

Mario Allegra, Antonella D’Anneo, Anna Frazzitta, Ignazio Restivo, Maria Antonia Livrea, Alessandro Attanzio * and Luisa Tesoriere *

Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche, Università di Palermo, 90123 Palermo, Italy; mario.allegra@unipa.it (M.A.); antonella.danneo@unipa.it (A.D.); anna.frazzitta@unipa.it (A.F.); ignazio.restivo@unipa.it (I.R.); maria.livrea@unipa.it (M.A.L.)

* Correspondence: alessandro.attanzio@unipa.it (A.A.); luisa.tesoriere@unipa.it (L.T.)

Received: 27 May 2020; Accepted: 28 June 2020; Published: 2 July 2020

Abstract: Combining phytochemicals with chemotherapics is an emerging strategy to treat cancer to overcome drug toxicity and resistance with natural compounds. We assessed the effects of indicaxanthin (Ind), a pigment obtained from <i>Opuntia ficus-indica</i> (L. Mill) fruit, combined with cisplatin (CDDP) against cervical cancer cells (HeLa). Measured cell viability via Trypan blue assay; cell morphology via fluorescence microscopy; apoptosis, cell cycle, mitochondrial membrane potential (MMP) and cell redox balance via flow-cytometry; expression levels of apoptosis-related proteins via western blot. Cell viability assays and Chou-Talalay plot demonstrated that the combination of CDDP and Ind had synergistic cytotoxic effects. Combined treatment had significant effects (p < 0.05) on phosphatidylserine externalization, cell morphological changes, cell cycle arrest, fall in MMP, ROS production and GSH decay compared with the individual treatment groups. Bax, cytochrome c, p53 and p21<sup>waf1</sup> were over-expressed, while Bcl-2 was downregulated. Pre-treatment with N-acetyl-l-cysteine abolished the observed synergistic effects. We also demonstrated potentiation of CDDP anticancer activity by nutritionally relevant concentrations of Ind. Oxidative stress-dependent mitochondrial cell death is the basis of the chemosensitizing effect of Ind combined with CDDP against HeLa cancer cells. ROS act as upstream signaling molecules to initiate apoptosis via p53/p21<sup>waf1</sup> axis. Ind can be a phytochemical of interest in combo-therapy.

Keywords: combo-therapy; oxidative stress; phytochemicals; indicaxanthin; <i>Opuntia ficus indica</i> (L. Mill); cancer; cisplatin

1. Introduction

Cisplatin (cis-diamminedichloro platinum(II), CDDP) is a first-generation platinum complex chemotherapeutic drug extensively employed in the treatment of many human solid tumors such as cervical cancer [1]. Its mode of action has been linked to the ability to damage DNA through crosslinking with the purine bases. When the DNA damage is beyond repair, the cells undergo a programmed cell death [2]. In addition, other mechanisms, such as the production of reactive oxygen species (ROS), are involved in the drug toxicity. CDDP-induced oxidative stress primarily targets mitochondrion [3]. This results in loss of protein sulfhydryl groups, inhibition of calcium uptake and fall of mitochondrial membrane potential (MMP) [3]. In spite of its effectiveness, its severe adverse effects, including renal and hepatic dysfunction, anemia and leucopenia [4] as well as the generation of chemo-resistance, limit the clinical use of CDDP [5].

The drug combination therapy is considered an effective strategy in cancer treatment to overcome chemotherapy toxicity because of lower doses required. Recently there has been a growing interest...
in the use of natural chemo-preventive agents such as phytochemicals that, acting in synergy with commercial drugs, bring about an enhanced effect [6–11]. A large number of these compounds are commonly included in the human diet, bioavailable and, more importantly, do not exert toxic effects at the absorbed amounts.

Indicaxanthin ((2S)-2,3-dihydro-4-[2-[(2S)-2α-carboxypyrrolidin-1yl]ethenyl]pyridine-2α,6-dicarboxylic acid, Ind), the yellow pigment characterizing the edible fruit of the cactus Opuntia ficus-indica (L. Mill), is a water-soluble alkaloid belonging to the class of betalain phytochemicals (Figure 1). Extensive research over the years has demonstrated that Ind has a variety of biological properties and exerts pharmacological antioxidant [12] and anti-inflammatory [13,14] effects. Most recently, its chemopreventive and antitumor activity in vitro and in animals has also been demonstrated [15–17]. In the human Caco2 colon cancer cell line, anti-proliferative and pro-apoptotic effects of Ind are associated with re-activation of the expression of the onco-suppressor p16 INK4a through the induction of the demethylation of its promoter region [15]. Ind inhibits the growth of other colorectal cancer cell lines, such as LOVO1, HCT116, and DLD1 cells and influences their DNA methylation status by affecting expression and activity of DNA methyltransferase enzyme [16]. In A375 human melanoma cells, Ind is able to induce apoptosis by inhibiting NF-κB activation and regulating the expression of NF-κB-dependent anti-apoptotic proteins [17]. Finally, in a xenograft model of cutaneous melanoma, the phytochemical orally administered to mice impairs tumor progression and reduces plasma levels of melanoma-associated chemokines [17]. On the other hand, interestingly, Ind, until 200–250 μM is not able to affect viability of non-cancer cells such as normal human epidermal melanocytes [17] or intestinal normal-like differentiated Caco-2 cells [15].

![Figure 1. Molecular structure of indicaxanthin.](image)

Based on this knowledge, the present study has assessed the effects of a combination of Ind and CDDP on growth, cell cycle progression and apoptosis in HeLa cells and researched molecular mechanisms involved in the observed synergism. Moreover, as Ind is a highly bioavailable phytochemical in humans [18], potentiation of anticancer activity of CDDP toward HeLa cells by nutritionally relevant concentrations of Ind has also been investigated.

2. Materials and Methods

All materials and reagents were acquired from Sigma-Aldrich Chemical Co (St. Louis, MO, USA), unless otherwise specified. Solvents were of HPLC grade. We purchased HeLa (cervical cancer cells) from the American Type Culture Collection (Rockville, MD, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with L-glutamine (2 mM), 10% fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin (100 μg/mL) and gentamicin (5 μg/mL). Cells were maintained in log phase by seeding in flasks twice a week at a density of 5.0 × 10⁴ cells/cm² in humidified 5% CO₂ atmosphere, at 37 °C.
Ind was isolated from *Opuntia ficus indica* (L. Mill) fruit pulp (yellow cultivar) and purity (97%) of the pigment was assessed by HPLC according to a previously described method [17].

2.1. Cytotoxicity Assay In Vitro

The effect of CDDP and Ind on the cell viability was measured by trypan blue exclusion test [19]. Briefly, HeLa cells were seeded at $5.0 \times 10^4$ cells/cm$^2$ in 96-well plates containing 200 03BCL DMEM and allowed to adhere through overnight incubation. Then, cells in subconfluence were washed with fresh medium and incubated for 24 h with various concentrations of CDDP (from 1 to 100 $\mu$M) or Ind (from 1 to 200 $\mu$M) in DMEM. Before use, Ind (40 mM) in phosphate-buffered saline solution, pH 7.4, (PBS) was filter-sterilized (0.2 $\mu$m filters, Millipore, Milan, Italy). CDDP was dissolved in dimethyl sulfoxide (DMSO) and then diluted in culture medium so that the effective DMSO concentration did not exceed 0.1%. No differences were found between cells treated with 0.1% DMSO and untreated cells in terms of cell number and viability. After treatment, media were aspirated carefully and the plate gently washed with PBS. Then, cells attached to the culture plastic were collected after 0.25% trypsin-EDTA treatment and mixed with an equal volume of 0.4% trypan blue. Unstained (viable) and stained (nonviable) cells were separately counted in a hemocytometer chamber (Neubauer’s chamber) under a light microscope (Carl Zeiss, Oberkochen, Germany). Cell viability was expressed as a percentage of total number of viable cell divided by total number of cells. IC$_{50}$ value was defined as the molar concentration of the compound that inhibits 50% cell viability and calculated by the dose-response inhibition model in GraphPad Prism 5.02 (GraphPad Software, San Diego, CA, USA).

2.2. Estimation of Combination Index to Determine Interaction of CDDP with Ind

The Chou and Talalay method was used to investigate the combined effect of CDDP and Ind [20]. HeLa cells were treated with a range of concentrations of CDDP in combination with Ind at a fixed concentration ratio (1: 6), chosen on the IC$_{50}$ values of the compounds when used alone. The concentration ranges were: Cis: 5–25 $\mu$M; Ind: 30–150 $\mu$M. After 24 h, cell growth was examined using Trypan blue method as above reported. In selected experiments, pre-treatment with N-acetyl-L-cysteine (NAC, 2 mM) was done for 1 h before adding CDDP combined with Ind. The Combination Index (CI) was calculated using CompuSyn software (ComboSyn, Paramus, NJ, USA) to define the type of effect. CI is calculated for every fraction affected ($f_a$) value, where $f_a$ is defined as percentage inhibition/100. CI > 1, CI < 1 and CI = 1 indicate antagonism, synergism and additive effect respectively. We used the same software to calculate the dose reduction index (DRI). This is defined as the comparison of the dose of each drug alone with the degree of dose reduction of the combined drugs for the same degree of effect.

2.3. Flow Cytometry

2.3.1. Measurement of Phosphatidylserine Exposure

Cell double staining with annexin V/propidium iodide (PI) was used to detect externalization of phosphatidylserine to the membrane surface by flow cytometry. Tumor cells were seeded in triplicate in 24-wells culture plates at a density of $5.0 \times 10^4$ cells/cm$^2$. Cells were incubated overnight and washed with fresh medium. Then, individual compounds or in combination were added. After 24 h incubation, cells were harvested by trypsinization, adjusted at $1.0 \times 10^6$ cells/mL with buffer according to the manufacturer’s instructions (eBioscience, San Diego, CA, USA) and submitted to double staining with annexin V/PI as previously described [21]. We analyzed samples of at least $1.0 \times 10^4$ cells by fluorescence-activated cell sorting (FACS) using Epics XL™ flow cytometer (Expo32 software, Beckman Coulter, Fullerton, CA, USA).
2.3.2. Cell Cycle Analysis

Aliquots of $1.0 \times 10^6$ cells were harvested by centrifugation, washed with PBS and incubated for 30 min, at room temperature in the dark in a PBS solution containing Triton X100 (0.1%, $v/v$), 20 µg/mL PI and 200 µg/mL RNase. Then samples were immediately subjected to FACS analysis. At least $1 \times 10^4$ cells were analyzed for each sample.

2.3.3. Measurement of Mitochondrial Transmembrane Potential (MMP)

The cationic lipophilic dye 3,3′-dihexyloxacarbocyanine iodide (DiOC6) (Molecular Probes, Inc., Life Technologies Italia, Monza, Italy) was used to assess the MMP. DiOC6 accumulates in the mitochondrial matrix and a reduction in the DiOC6-induced fluorescence intensity indicates a decrease of mitochondrial membrane potential ($\Delta \Psi_m$). Cells were treated for 24 h, then incubated with DiOC6 at a 40 nmol/L final concentration, for 15 min at 37°C. Cells were collected by centrifugation, washed with PBS and suspended in 500 µL PBS. Then samples of at least $1.0 \times 10^4$ cells were subjected to FACS analysis.

2.3.4. Intracellular Reactive Oxygen Species (ROS) and Glutathione (GSH)

Fluorescent probes 2′,7′-dichlorofluorescin diacetate (DCFDA) or 5-chloromethylfluorescein diacetate (CMFDA), were used to cytofluorimetrically measure intracellular levels of ROS and GSH, respectively [22]. Thirty minutes before ending the cell treatment, DCFDA or CMFDA at 10 µM and 1 µM final concentration, respectively, were added to the medium. Then the cells were washed with PBS, resuspended in the same buffer and analyzed.

2.4. Fluorescence Microscopy

After 24 h treatment, the cells were rinsed with PBS and stained with acridine orange and ethidium bromide (AO/EB) fluorescent dyes in Hank’s buffer, as described previously [23]. The cells were examined by fluorescence microscopy (Leica Microsystems, Wetzlar, Germany). Intact cells appeared green, with uncompromised nuclei. Chromatin condensation and nuclear fragmentation in early apoptotic cells caused them to be stained green with bright green dots. Lost membrane integrity and condensed and fragmented orange chromatin was displayed in late apoptotic cells. Condensed chromatin was not evident in necrotic cells nuclear morphology although also stained orange. Images were taken with an inverted fluorescence microscope equipped by a CCD camera (Leica Microsystems, Wetzlar, Germany). Rhodamine and fluorescein isothiocyanate (FITC) filters were used for red and green fluorescent cells, respectively. Micrographs reported in results section are merged after combining red and green channels by Leica Q Fluo software (Leica Microsystems, Wetzlar, Germany).

2.5. Western Blotting

After treatment, cold PBS was used to rinse the cells. Cells were suspended in cell lysis buffer [0.5% sodium deoxycholate, 150 mM NaCl, 0.1% SDS, 1% NP-40, 50 mM Tris-HCl (pH 7.4), 20 mM NaF, 50 mM glycerophosphate, 20 mM EGTA, 0.5 mM PMSF, 1 mM DTT, and 1 mM Na$_3$VO$_4$] containing phosphatase- and protease inhibitors and sonicated (3 cycles, each for 10 sec in a Soniprep 150, Cellai Srl, Milano, Italia). After vigorously vortexing, samples were centrifuged at 12,000 rpm at 4°C for 30 min and supernatants were collected and stored at $-80$°C. Bradford reagent was used to determine the concentration of proteins. Equal amounts of protein samples (40 µg/lane), were separated on 10% gel by discontinuous SDS-PAGE and then electrotransferred to a polyvinylidiene difluoride membrane (Millipore, Merck, Darmstadt, Germany). The immunoblot was incubated overnight at 4°C with blocking solution (5% skim milk), followed by incubation with a 1: 200 dilution of anti-Bax monoclonal antibody (clone YTH6A7, Cat No. SC-80658, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Bcl-2 (C-2, Cat No. SC-7382, Santa Cruz Biotechnology), anti-cytochrome c (A-8, Cat No. SC-13156, Santa Cruz Biotechnology), anti-p53 (DO-1, Cat No SC-126, Santa Cruz Biotechnology)
or anti-p21waf1 (F-5, Cat No SC-6246 Santa Cruz Biotechnology) for 1 h at room temperature. Blots were washed two times with Tris-buffered saline/Tween 20 (TBST) and incubated with a 1: 2000 dilution of horseradish peroxidase (HRP)-conjugated anti-IgG antibody (Dako Denmark, Glostrup, Denmark) for 1 h at room temperature. After washing with TBST, blots were developed by enhanced chemiluminescence (Amersham Life Science, Arlington Heights, IL, USA). Quantity One Imaging Software (Bio-Rad Laboratories, Hercules, CA, USA) was used to analyze the optical density of the bands. Ponceau red staining and immunoblotting for β-tubulin (D-10, Cat No. SC-5274, Santa Cruz Biotechnology) were used to verify the correct protein loading. The results of the densitometric analysis were reported as arbitrary densitometric units normalized to β-tubulin.

2.6. Statistical Analysis

Results are given as means ± standard deviations (SD). Unless stated otherwise, three independent observations were performed for each experiment, thrice replicated. Statistical software (GraphPad Software) with a test for normality followed by one-way ANOVA and Tukey’s correction was used. Mean values without a common symbol were significantly different at p < 0.05.

3. Results

3.1. Growth-Inhibitory Effect of CDDP and Ind Alone and in Combination

The effects of CDDP, Ind and CDDP combined with Ind on the viability of HeLa cells were evaluated by the trypan-blue staining method (Figure 2a). After 24 h of treatment with the individual compounds, the calculated 50% inhibitory concentrations (IC_{50}) of CDDP and Ind were 23.91 ± 1.3 µM and 149.55 ± 10.2 µM, respectively (n = 9). The inhibitory effect of CDDP/Ind co-treatment was studied using equipotent combinations of various doses of the two drugs according to the combination index theorem of Chou and Talalay based on the median-effect equation [20]. The combination index (CI) values for different inhibition fractions (f_a) of growth of HeLa cells were calculated and are shown as a function of the effect level (Figure 2b). CI values were quite similar at each assayed dose and far below a value of 1.0, indicating synergism between the two drugs in a wide range of concentrations. The strongest synergy between the drugs (0.66) was calculated at 0.5 fractional inhibition of growth of HeLa, while the dose reduction index (DRI) values indicated that the effective CDDP dose in synergistic combination with Ind could be reduced to about 2 times and up to 3 times (Table 1). (C-I) (5/30 µM; 7.5/45 µM; 12.5/75 µM; 20/120 µM, 25/150 µM) (a) and plot of the combination index vs. fraction of cells affected obtained using the median-effect analysis program (b).

Figure 2. Cont.
Figure 2. Effect on the viability of HeLa cells of CDDP (1–100 µM), Ind (1–200 µM), and CDDP combined with Ind (C-I) (5/30 µM; 7.5/45 µM; 12.5/75 µM; 20/120 µM, 25/150 µM) (a) and plot of the combination index vs. fraction of cells affected obtained using the median-effect analysis program (b).

Table 1. Dose-response association of CDDP and Ind alone or in combination.

| Compound | IC<sub>50</sub> (µM) | r  | CI Values | DRI Values |
|----------|---------------------|----|-----------|------------|
|          |                     |    | f<sub>a 0.25</sub> | f<sub>a 0.5</sub> | f<sub>a 0.75</sub> | f<sub>a 0.25</sub> | f<sub>a 0.5</sub> | f<sub>a 0.75</sub> |
| CDDP     | 23.91               | 0.99 | 0.71       | 0.66       | 0.76       | 3.72       | 2.97       | 2.30       |
| Ind      | 149.55              | 0.93 |            |            |            | 2.25       | 3.06       | 4.16       |
| CDDP/Ind | 56.51               | 1.00 |            |            |            |            |            |            |

DRI, dose reduction index; r, correlation coefficient.

3.2. Induction of Apoptosis by CDDP and Ind Alone and in Combination

To explore the mechanisms underlying the inhibitory effects of the two agents on HeLa cells proliferation, the fraction of apoptotic cells treated for 24 h with CDDP and Ind alone or in combination, at the ratio of their IC<sub>50</sub> values (1: 6), was determined by flow cytometry using Annexin V-FITC/PI double staining. As shown in Figure 3 the percentage of apoptotic cells increased in both the CDDP (10 µM) and Ind (60 µM) groups compared with that of the control (25.4 ± 1.9 and 15.3 ± 2.8 vs 0.9 ± 0.1%). In addition, the CDDP/Ind combination treatment caused a more significant apoptosis than CDDP treatment alone (35.9 ± 2.6 vs 25.4 ± 1.9%).
Alterations in the cell cycle caused by a 24 h treatment of HeLa cells with CDDP and Ind were determined by labelling the DNA with propidium iodide and analyzing with flow cytometer. When compared to untreated cells (control), CDDP significantly reduced the number of cells in G2/M phase with a concomitant increased in S phase and appearance of a subG0/G1-cell population (Figure 5). On the contrary, treatment of the cells with Ind induced an accumulation of cells in phase G0/G1 with
a reduction in G2/M, while percentage of cells in S phase appeared unchanged. Interestingly, when CDDP/Ind combination was used, the cell cycle distribution resulted significantly different ($p < 0.05$) from that observed. Indeed, the combined treatment caused a remarkable increase of cells in G0/G1 phase, an almost total absence of cells in G2/M phase and an increased percentage of sub G0/G1 cell population.

3.4. Effect of CDDP and Ind Alone and in Combination on Mitochondrial Membrane Potential (MMP)

Mitochondrial dysfunction is an early marker of mitochondria-mediated cell apoptosis. We measured the depolarization of MMP ($\Delta \Psi_m$) using DiOC6, a fluorescent mitochondria-specific and voltage-dependent dye. This showed that treatment for 24 h with 10 µM CDDP or 60 µM Ind alone, resulted in an increased of MMP depolarization compared to control groups (19.7 ± 1.6% and 13.2 ± 1.2%, respectively vs 8.4 ± 0.3%) ($p < 0.05$). However, with the combined use of CDDP/Ind, the $\Delta \Psi_m$ increased to 23.8 ± 1.8% (Figure 6).

Figure 6. Depolarization of mitochondrial membrane potential induced by CDDP, Ind and CDDP/Ind combination on HeLa cells. Cells were treated for 24 h as described in Methods. Then percentage of DiOC6 stained-HeLa cells were determined by flow cytometer and compared to untreated cells (control). (a) Mean values ±SD of three separate experiments in triplicate. Bars without a common symbol are significantly different with $p < 0.05$ (one-way Anova associated with Tukey’s post hoc test); (b) Representative images.
3.5. Effect of CDDP and Ind Alone and in Combination on Expression of Apoptosis-Related Proteins

Mitochondrial dysfunction governs the intrinsic apoptosis pathway. We used western immunoblotting to assess the levels of Bax, Bcl-2 and cytochrome c as markers of this process. When compared to untreated cells (control), treatment with Ind alone did not change the level of the examined proteins, while expression of Bax and cytochrome c were markedly increased as well as that of Bcl-2 decreased by CDDP ($p < 0.05$). Interestingly, combined treatment with CDDP/Ind significantly raised the levels of Bax and cytochrome c with reduced Bcl-2 level when compared to the treatment with CDDP alone (Figure 7).

![Western Blot Image]

**Figure 7.** Effect of CDDP, Ind and CDPP/Ind on expression of apoptosis- and cell cycle-related proteins in HeLa cells. Cells were treated for 24 h as described in Methods. Representative images of immunoblotting analysis of Bax, Bcl-2, cytochrome c, p53 and p21waf1 levels and mean values ±SD of the densitometric analysis of four separate experiments. β tubulin was used as the internal control. au, arbitrary units. Bars without a common symbol are significantly different with $p < 0.05$ (one-way Anova associated with Tukey’s post hoc test).

Bax and Bcl2 genes are regulated by p53 transcription factor [24]. In HeLa cells we found that CDDP upregulated p53 levels. A higher p53 expression ($p < 0.05$) was found in cells co-treated with CDDP and Ind (Figure 7). Among the transcriptional targets of p53, also p21waf1 plays important roles in regulating cell growth arrest and apoptosis [25]. Combined treatment with CDDP and Ind significantly increased the p21waf1 level relative to the treatment with CDDP alone ($p < 0.05$) (Figure 7).

3.6. Effect of CDDP and Ind Alone and in Combination on the Cell Redox Balance

Oxidative stress is one of the most important mechanisms involved in CDDP toxicity. Intracellular ROS production and GSH levels in HeLa cells were measured by cytofluorimetric analysis using DCFDA or CMFDA as appropriate fluorescence probes, respectively. Treatment for 24 h of the cells with CDDP at 10 μM caused a significant increase of the ROS levels ($+11.6 \pm 1.6\%$) associated to a drop in GSH content ($-18.9 \pm 1.2\%$) in comparison to control cells, respectively ($p < 0.05$) (Figure 8). On the other hand Ind (60 μM) did not significantly vary the DCFDA-associated fluorescence neither changed GSH content compared to untreated cells. Interestingly, when the two drugs were simultaneously added, we measured an increase of ROS production ($+22.3 \pm 2.1\%$) and a reduction in GSH content ($31.8 \pm 1.1\%$), more remarkable than that caused by CDDP (Figure 8).
Figure 8. Cell redox unbalance induced in HeLa by CDDP, Ind and CDDP/Ind combination. ROS production and GSH levels were evaluated cytofluorimetrically after 24 h treatment by staining of the cells with DCFDA and CMFDA, respectively. Compared to untreated cells (control). (a) Mean values ±SD of three separate experiments in duplicate. Within the same parameter, means without a common symbol are significantly different with p < 0.05 (one-way Anova associated with Tukey’s post hoc test); (b) Representative images of ROS production. (c) Representative images of intracellular GSH levels.

3.7. Pretreatment with NAC Prevents Apoptosis Induced by CDDP and Ind

To assess whether the elevated redox unbalance was related to the apoptosis induced by the combination of CDDP and Ind, HeLa cells were pretreated for 1 h with 2 mM NAC, a general ROS scavenger, followed by treatment with CDDP (10 µM) plus Ind (60 µM) for 24 h. The ROS levels and the proportion of apoptotic cells were determined by flow cytometric analysis. Treatment of the cells with NAC alone did not influence any of the measured parameters (Figure 9). On the contrary, NAC prevented the ROS generation in HeLa cells treated with CDDP/Ind and the percentage of apoptotic cells, following the combined treatment, was reduced from 34.90 ± 2.19% in the NAC untreated group to 13.57 ± 0.19% in the NAC treated group (Figure 9); the difference was statistically significant (p < 0.05). Notably, pre-incubation of the cells with 2 mM NAC before adding of CDDP/Ind, significantly attenuated the p53, Bax and cytochrome c expression levels measured in the absence of the antioxidant, while Bcl2 increased (Figure 9). However, NAC, except for the ROS production, failed to restore the control values.
antioxidant, while Bcl2 increased (Figure 9). However, NAC, except for the ROS production, failed to restore the control values.

Figure 9. Pretreatment of HeLa cells with NAC prevents ROS-dependent apoptosis and modulates levels of apoptotic regulators induced by CDDP/Ind combination. Cells were treated for 24 h as described in Methods. (a) Intracellular ROS levels by flow cytometry using DCFA staining; (b) Apoptosis assay by flow cytometry using Annexin V-FITC/PI double staining; (c) Immunoblotting analysis of p53, Bax, Bcl-2 and cytochrome c levels with densitometric analysis. β-tubulin was used as the internal control. Representative images and mean values ±SD of three separate experiments. Means without a common symbol are significantly different with p < 0.05 (one-way Anova associated with Tukey’s post hoc test). au, arbitrary units.

3.8. Potentiation of the CDDP Cytotoxic Activity by Ind

We also investigated the potentiation of the anticancer effects of CDDP on HeLa cells by low concentrations of Ind. HeLa cells were incubated with Ind at 2, 5 or 10 µM in the absence or in the presence of variable concentrations of CDDP and cell viability was measured after 24 h of treatment. While Ind alone did not affect HeLa viability at any considered concentration (not shown), when the phytochemical was added in medium containing CDDP it caused an evident increase of the cytotoxic
effect of the chemotherapeutic agent, such that higher the Ind amount was lower the cell vitality measured after treatment (Figure 10). When comparing the calculated IC\textsubscript{50} values, co-treatment of Hela cells with 10 µM Ind lowered about three times the concentration of CDDP required for the reduction of the cell growth (Figure 10).

Figure 10. Cytotoxic effect of CDDP on HeLa cells in the absence or in the presence of not toxic Ind concentrations. Cells were treated for 24 h as described in Methods. IC\textsubscript{50} values are the mean ±SD of three separate experiments in triplicate. Means with different superscript letters are significant \( p < 0.05 \) (one-way Anova associated with Tukey’s post hoc test).

4. Discussion

Emerging evidence suggests that cancer-preventative phytochemicals may be combined with chemotherapeutic drugs for a more effective treatment of cancer. Dietary compounds such as genistein, curcumin, epigallocatechin-3-gallate, resveratrol and apigenin have all been recognized as tumor-preventing agents [26,27]. Their capacity of enhancing anticancer activity or minimizing the resistance of cancer cells to a number chemotherapeutics has been explored [7,9]. Ind, the characteristic pigment of cactus pear fruits, is a redox-active compound able to exert important poly-pharmacological effects included antiproliferative and tumor suppressor effects both in vivo and in vitro [15–17,28] and may have a chemopreventive potential. In this study, we show that Ind individually exhibits growth inhibitory activity on HeLa cervical cancer cells and when combined with CDDP cooperates in producing an enhanced anti-tumor effect against these cells. The chemosensitizing effect of Ind in combination with CDDP is causally associated with p53-dependent mitochondrial cell death pathway induced by oxidative stress.
Both Ind alone and CDDP alone were validated to have inhibitory effects on HeLa cells in a dose-dependent manner. Our data, obtained from the Combination Index analysis, demonstrated that combination regimens with Ind and CDDP produced significant synergistic anticancer effects (CI < 1) in a large range of concentrations. CDDP primarily exhibits its anticancer effects by inducing apoptosis in cancer cells [29]. Flow cytometry and fluorescence microscopy analysis showed that CDDP/Ind combined treatment caused a more significant apoptosis in HeLa cells than either CDDP or Ind treatment alone. As recent evidences suggest that the apoptosis induction efficacy of antitumor drugs gradually decreases due to chemoresistance [30,31], our results suggest that Ind may be a potential candidate for strengthening the apoptotic effect of low CDDP doses, then delaying the unwanted effect of chemoresistance of the drug in the cervical tumor.

A number of checkpoints that ensure the accuracy and integrity of the DNA replication control cell cycle progression. Cancer is associated with defects in the cell cycle checkpoints, which prevent the cycle from stopping in spite of adverse conditions. One of the anticancer mechanisms of CDDP is the activation of cell cycle checkpoints, which induce a transient S-phase arrest of cancer cells [29], as also shown in our study. However, the combination of Ind and CDDP caused a block of the cell cycle at G0/G1 phase, indicating that chemosensitization occurs during the execution of the G1 phase. The induction of p21\textsuperscript{waf1}, known to silence the G1/S-promoting cyclin E/CDK2 kinase [25], detected in HeLa cells co-treated with CDDP/Ind, can account for the observed inhibition of the cell cycle transition with G0/G1 arrest. Other natural chemopreventive agents, such as myricetin and methyl eugenol in combination with CDDP have been reported to significantly induce an arrest of HeLa cells in the G0/G1 phase [10].

Mitochondria support and play a critical role in apoptosis and a fall of MMP, caused by an increment of Bax/Bcl2 ratio, is a crucial event in the intrinsic cell death pathway [32]. In the present study, the MMP of HeLa cells was significantly decreased in the CDDP/Ind group, compared with that in the CDDP-alone; in addition a stronger decrease in the antiapoptotic protein Bcl-2 with an increase in the proapoptotic proteins Bax were evidenced. These results demonstrated that combined treatment with CDDP/Ind can effectively induce apoptosis in HeLa cells through the mitochondrial apoptotic pathway.

p53 is a key protein for several fundamental cellular signaling pathways [33]. The most important of these pathways for p53’s tumor-suppressive role are the induction of apoptosis and cell cycle arrest [34]. p53 acts as a sequence-specific nuclear transcription factor that regulates transcription of genes controlling mitochondrial permeability, such as Bcl2 protein family, as well as the cell cycle progression, such as p21\textsuperscript{waf1} [35]. In our study, immunoblotting analysis revealed an increased accumulation of p53 in HeLa cells co-treated with CDDP and Ind with respect to cells treated with CDDP alone. These results indicate that Ind cooperatively amplified the CDDP cytotoxic effect through induction of p53 and p53 regulated proapoptotic and growth inhibitory gene expression. Similarly crocin, a naturally derived compound obtained from the stigma of Crocus sativus (saffron) and crocetin, the major constituent of saffron, have been reported to enhance the chemosensitivity of CDDP in lung and esophagus cancer cells, respectively, by upregulation of p53/p21\textsuperscript{waf1} and Bax levels with a concomitant decrease of Bcl-2 [36,37].

Cancer cells are usually under a higher oxidative stress than normal cells and an additional increment of the ROS generation can trigger cell death [38–40]. Main antineoplastic drugs that are currently used for cancer chemotherapy such as anthracyclines, taxanes and platinum-related compounds, including cisplatin, induce higher oxidant levels [41,42]. Accordingly, the combination of natural compounds with chemotherapics to increase the redox state to the condition of oxidative stress may be considered a successful adjuvant therapy against cancers. Ind is a redox active compound capable of both antioxidant and pro-oxidant effects, depending on its concentration [12,43]. In our study, although Ind alone at 60 µM was not capable of significantly modifying the redox status of HeLa cells in comparison with the control group, when combined with CDDP caused a net raise of ROS and a more marked decay of GSH content respect to CDDP alone group. Moreover, we found that
pre-treatment with the ROS scavenger NAC blunted the CDDP plus Ind-induced PS externalization as well as the expression of mitochondrial apoptosis-related proteins. Collectively, our data demonstrates that the chemo sensitizing effect of Ind in combination with CDDP is causally associated with oxidative stress-mediated mitochondrial cell death pathway and that ROS act as an upstream signaling molecule to initiate p53-mediated apoptosis when HeLa cells were co-treated with CDDP and Ind. Considering these encouraging data, our future studies will be directed toward the analysis of the chemotherapeutic or chemosensitizer potential of Ind when used in combination with the most common anti-neoplastic agents in animal tumor models.

Dietary modification for patients receiving chemotherapy has been a regular practice to aid better digestion and adequate nutrition. Today, the intake of food as a dietary intervention to provide a variety of chemotherapeutic-sensitizing natural agents and overcome chemoresistance is a novel concept in oncology [44]. Ind is a highly bioavailable phytochemical. After a single ingestion of 500 g of cactus pear fruit pulp, it reaches in humans a maximum plasma concentration of about 7.0 µM at 3 h after eating the fruits [18]. We show that pre-treatment of Hela cells with Ind at low micromolar concentrations of nutritional relevance, significantly potentiates the cytotoxic action of CDDP, reducing its semi-maximal effective dose. Other studies in healthy men and women have provided a good indication of the potential of this fruit to positively affect the body’s redox balance, to decrease oxidative damage to lipids and improve antioxidant status and the response of the immune system [45,46]. Our data suggests that diet intervention with Opuntia cactus pear fruits in patients with cervical cancer undergoing chemotherapy might be considered with the aim to provide Ind as a chemosensitizer of the therapy.

**Author Contributions:** Conceptualization, L.T. and M.A.; methodology, A.D., A.F., A.A. and I.R.; software, A.F. and I.R.; investigation, L.T. and M.A.; data curation, A.D. and A.A.; writing—original draft preparation, L.T.; writing—review and editing, M.A., L.T. and M.A.L.; visualization, A.A.; supervision, M.A.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This project was funded by a 2014–2020 PON Ricerca e Innovazione grant from the Italian Ministry of Education, University and Research, European Union, entitled “PROGEMA—Processi Green per l’Estrazione di Principi Attivi e la Depurazione di Matrici di Scarto e Non” (ARS01_00432) to P.C.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Lorusso, D.; Petrelli, F.; Coinu, A.; Raspagliesi, F.; Barni, S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. *Gynecol. Oncol.* 2014, 133, 117–123. [CrossRef]
2. Dasari, S.; Tchounwou, P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. *Eur. J. Pharmacol.* 2014, 740, 364–378. [CrossRef]
3. Saad, S.Y.; Najjar, T.A.; Alashari, M. Role of non-selective adenosine receptor blockade and phosphodiesterase inhibition in cisplatin-induced nephrogonadal toxicity in rats. *Clin. Exp. Pharmacol. Physiol.* 2004, 31, 862–867. [CrossRef] [PubMed]
4. Astolfi, L.; Ghiselli, S.; Guaras, V.; Chicca, M.; Simoni, E.; Olivetto, E.; Lelli, G.; Martini, A. Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation. *Oncol. Rep.* 2013, 29, 1285–1292. [CrossRef] [PubMed]
5. Kirwan, J.M.; Symonds, P.; Green, J.A.; Tierney, J.; Collingwood, M.; Williams, C.J. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. *Radiother. Oncol.* 2003, 68, 217–226. [CrossRef]
6. Fulda, S.; Debatin, K.M. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. *Oncogene* 2004, 23, 6702–6711. [CrossRef]
7. Sarkar, F.H.; Li, Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. *Cancer Res.* 2006, 66, 3347–3350. [CrossRef] [PubMed]
8. Ruixuan, W.; Lijie, M.; Dan, W.; Jiahui, Y.; Xueying, L.; Faguang, J. Gallic acid induces apoptosis and enhances the anticancer effects of cisplatin in human small cell lung cancer H446 cell line via the ROS-dependent mitochondrial apoptotic pathway. Oncol. Rep. 2016, 35, 3075–3083.

9. Tan, B.L.; Norhaizan, M.E. Curcumin combination chemotherapy: The implication and efficacy in cancer. Molecules 2019, 24, 2527. [CrossRef]

10. Yi, J.L.; Shi, S.; Shen, Y.L.; Wang, L.; Chen, H.Y.; Zhu, J.; Ding, Y. Myricetin and methyl eugenol combination enhances the anticancer activity, cell cycle arrest and apoptosis induction of cis-platin against HeLa cervical cancer cells. Int. J. Clin. Exp. Pathol. 2015, 8, 1116–1127. [PubMed]

11. Sun, C.Y.; Zhang, Q.Y.; Zheng, G.J.; Feng, B. Phytochemicals: Current strategy to sensitize cancer cells to cisplatin. Biomed. Pharmacother. 2019, 110, 518–527. [CrossRef] [PubMed]

12. Tesoriere, L.; Allegra, M.; Butera, D.; Gentile, C.; Livrea, M.A. Kinetics of the lipoperoxyl radical-scavenging activity of indicaxanthin in solution and unilamellar liposomes. Free Radic. Res. 2007, 41, 226–233. [CrossRef]

13. Allegra, M.; Ianaro, A.; Tersigni, M.; Panza, E.; Tesoriere, L.; Livrea, M.A. Indicaxanthin from cactus pear fruit exerts anti-inflammatory effects in carrageenan-induced rat pleurisy. J. Nutr. 2014, 144, 185–192. [CrossRef] [PubMed]

14. Tesoriere, L.; Attanzio, A.; Allegra, M.; Gentile, C.; Livrea, M.A. Indicaxanthin inhibits NADPH oxidase (NOX)-1 activation and NF-kappaB-dependent release of inflammatory mediators and prevents the increase of epithelial permeability in IL-1beta-exposed Caco-2 cells. Br. J. Nutr. 2014, 111, 415–423. [CrossRef]

15. Naselli, F.; Tesoriere, L.; Caradonna, F.; Bellavia, D.; Attanzio, A.; Gentile, C.; Livrea, M.A. Anti-proliferative and proapoptotic activity of whole extract and isolated indicaxanthin from Opuntia ficus-indica associated with re-activation of the onco-suppressor p16 INK4a gene in human colorectal carcinoma (Caco-2) cells. Biochem. Biophys. Res. Commun. 2014, 450, 652–658. [CrossRef]

16. Naselli, F.; Belshaw, N.J.; Gentile, C.; Tutone, M.; Tesoriere, L.; Livrea, M.A.; Caradonna, F. Phytochemical Indicaxanthin Inhibits Colon Cancer Cell Growth and Affects the DNA Methylation Status by Influencing Epigenetically Modifying Enzyme Expression and Activity. J. Nutr. Nutr. 2015, 8, 114–127. [CrossRef] [PubMed]

17. Allegra, M.; De Cicco, P.; Ercolano, G.; Attanzio, A.; Busa, R.; Cirino, G.; Tesoriere, L.; Livrea, M.A.; Ianaro, A. Indicaxanthin from Opuntia Ficus Indica (L. Mill) impairs melanoma cell proliferation, invasiveness, and tumor progression. Phytomedicine 2018, 50, 19–24. [CrossRef]

18. Tesoriere, L.; Allegra, M.; Butera, D.; Livrea, M.A. Absorption, excretion, and distribution of dietary antioxidant betalains in LDLs: Potential health effects of betalains in humans. Am. J. Clin. Nutr. 2004, 80, 941–945. [CrossRef]

19. Strober, W. Trypan Blue Exclusion Test of Cell Viability. Curr. Protoc. Immunol. 2015, 111, A3.B.1–A3.B.3. [CrossRef]

20. Chou, T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70, 440–446. [CrossRef]

21. Tesoriere, L.; Attanzio, A.; Allegra, M.; Gentile, C.; Livrea, M.A. Phytochemical indicaxanthin suppresses 7-ketocholesterol-induced THP-1 cell apoptosis by preventing cytosolic Ca2+ increase and oxidative stress. Br. J. Nutr. 2013, 110, 230–240. [CrossRef]

22. Attanzio, A.; D’Anneo, A.; Pappalardo, F.; Bonina, F.P.; Livrea, M.A.; Allegra, M.; Tesoriere, L. Phenolic Composition of Hydrophilic Extract of Manna from Sicilian Fraxinus angustifolia Vahl and its Reducing, Antioxidant and Anti-Inflammatory Activity in Vitro. Antioxidants 2019, 8, 494. [CrossRef] [PubMed]

23. Cascioferro, S.; Attanzio, A.; Di Sarno, V.; Musella, S.; Tesoriere, L.; Cirrincione, G.; Diana, P.; Farrino, B. New 1,2,4-oxadiazole nortopsentin derivatives with cytotoxic activity. Mar. Drugs 2019, 17, 35. [CrossRef] [PubMed]

24. Mello, S.S.; Attardi, L.D. Deciphering p53 signaling in tumor suppression. Curr. Opin. Cell Biol. 2018, 51, 65–72. [CrossRef] [PubMed]

25. Abbas, T.; Dutta, A. p21 in cancer: Intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9, 400–414. [CrossRef] [PubMed]

26. Surh, Y.J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 2003, 3, 768–780. [CrossRef]

27. Patel, D.; Shukla, S.; Gupta, S. Apigenin and cancer chemoprevention: Progress, potential and promise. Int. J. Oncol. 2007, 30, 233–245.
28. Allegra, M.; Tutone, M.; Tesoriere, L.; Almerico, A.M.; Culletta, G.; Livrea, M.A.; Attanzio, A. Indicaxanthin, a multi-target natural compound from Opuntia ficus-indica fruit: From its poly-pharmacological effects to biochemical mechanisms and molecular modelling studies. *Eur. J. Med. Chem.* 2019, 179, 753–764. [CrossRef]

29. Siddik, Z.H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. *Oncogene* 2003, 22, 7265–7279. [CrossRef]

30. Fraser, M.; Leung, B.; Jahani-Asl, A.; Yan, X.; Thompson, W.E.; Tsang, B.K. Chemoresistance in human ovarian cancer: The role of apoptotic regulators. *Reprod. Biol. Endocrinol.* 2003, 1, 66–79. [CrossRef]

31. Sasaki, H.; Sheng, Y.; Kotsuji, F.; Tsang, B.K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. *Cancer Res.* 2000, 60, 5659–5666. [PubMed]

32. Vyas, S.; Zaganjor, E.; Haigis, M.C. Mitochondria and Cancer. *Cell* 2016, 166, 555–566. [CrossRef] [PubMed]

33. Vousden, K.H.; Prives, C. Blinded by the light: The growing complexity of p53. *Cell* 2009, 137, 413–431. [CrossRef] [PubMed]

34. Vogelstein, B.; Lane, D.; Levine, A.J. Surfing the p53 network. *Nature* 2000, 408, 307–310. [CrossRef] [PubMed]

35. Bunz, F.; Dutriaux, A.; Lengauer, C.; Waldman, T.; Zhou, S.; Brown, J.P.; Sedivy, J.M.; Kinzler, K.W.; Vogelstein, B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. *Science* 1998, 282, 1497–1501. [CrossRef]

36. Chen, S.; Zhao, S.; Wang, X.; Zhang, L.; Jiang, E.; Gu, Y.; Shangguan, A.J.; Zhao, H.; Lv, T.; Yu, Z. Crocin inhibits cell proliferation and enhances cisplatin and pemetrexed chemosensitivity in lung cancer cells. *Transl. Lung Cancer Res.* 2015, 4, 775–783.

37. Li, S.; Shen, X.Y.; Ouyang, T.; Qu, Y.; Luo, T.; Wang, H.Q. Synergistic anticancer effect of combined crocetin and cisplatin on KYSE-150 cells via p53/p21 pathway. *Cancer Cell Int.* 2017, 17, 98–109. [CrossRef]

38. Aykin-Burns, N.; Ahmad, I.M.; Zhu, Y.; Oberley, L.W.; Spitz, D.R. Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. *Biochem. J.* 2009, 418, 29–37. [CrossRef]

39. Cieslak, J.A.; Cullen, J.J. Treatment of Pancreatic Cancer with Pharmacological Ascorbate. *Curr. Pharm. Biotechnol.* 2015, 16, 759–770. [CrossRef] [PubMed]

40. Fath, M.A.; Diers, A.R.; Aykin-Burns, N.; Simons, A.L.; Hua, L.; Spitz, D.R. Mitochondrial electron transport chain blockers enhance 2-deoxy-D-glucose induced oxidative stress and cell killing in human colon carcinoma cells. *Cancer Biol. Ther.* 2009, 8, 1228–1236. [CrossRef]

41. Barrera, G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. *ISRN Oncol.* 2012, 2012, 137289. [CrossRef] [PubMed]

42. Conklin, K.A. Chemotherapy-associated oxidative stress: Impact on chemotherapeutic effectiveness. *Integr. Cancer Ther.* 2004, 3, 294–300. [CrossRef] [PubMed]

43. Allegra, M.; D’Acquisto, F.; Tesoriere, L.; Attanzio, A.; Livrea, M.A. Pro-oxidant activity of indicaxanthin from Opuntia ficus indica modulates arachidonate metabolism and prostaglandin synthesis through lipid peroxide production in LPS-stimulated RAW 264.7 macrophages. *Redox Biol.* 2014, 2, 892–900. [CrossRef] [PubMed]

44. Bharti, A.C.; Aggarwal, B.B. *Role of Nutraceuticals in Cancer Chemosensitization*, 1st ed.; Elsevier: Amsterdam, The Netherlands, 2017; pp. 1–398.

45. Attanzio, A.; Tesoriere, L.; Vasto, S.; Pintaudi, A.M.; Livrea, M.A.; Allegre, M. Short-term cactus pear (Opuntia ficus-indica (L.) Mill) fruit supplementation ameliorates the inflammatory profile and is associated with improved antioxidant status among healthy humans. *Food Nutr. Res.* 2018, 62. [CrossRef]

46. Tesoriere, L.; Butera, D.; Pintaudi, A.M.; Allegre, M.; Livrea, M.A. Supplementation with cactus pear (Opuntia ficus-indica) fruit decreases oxidative stress in healthy humans: A comparative study with vitamin C. *Am. J. Clin. Nutr.* 2004, 80, 391–395. [CrossRef]